https://www.thebodypro.com/category/providing-quality-hiv-care/tag/interviews

The Latest

Catherine Hanssens.

Leading With a Public Health Response to COVID-19 in Prisons and Jails

Legal groups provide pathways to reducing coronavirus spread in carceral settings.

By Terri Wilder, M.S.W.
Lynne Mofenson

After Years of Decline, Perinatal HIV Transmission Has Hit a Plateau. Why?

This researcher has some ideas about what we need to do to address the problem.

By Terri Wilder, M.S.W.
cisgender woman prescription

Evaluating PrEP Uptake and Adherence in Cisgender Women—and What to Do About It

Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.

By Terri Wilder, M.S.W.
Governor Brian Kemp

Governor Brian Kemp’s COVID-19 Response Has Georgia On This HIV Doctor's Mind

Dr. Melanie Thompson discusses what’s happening in the state around coronavirus, and what it means for people living with HIV.

By Terri Wilder, M.S.W.
David Kalinoski

Creating Care Plans for People Who Use Drugs Or With Hepatitis C in the Time of Coronavirus

VOCAL-NY has kept its doors open through the COVID-19 pandemic to serve people who use drugs and may be living with hepatitis C, but how it provides services has changed.

By Terri Wilder, M.S.W.
Joshua St. Louis

How This Massachusetts Clinic Is Providing Transgender Care During the Coronavirus Pandemic

Telemedicine is helping keep transgender patients connected to care, but gaps still exist.

By Terri Wilder, M.S.W.
Winnie Byanyima

Addressing Coronavirus in African Countries With High HIV Rates: An Interview With UNAIDS Head Winnie Byanyima

Byanyima discusses COVID-19, HIV, and the power of the community response.

By Emily Bass
Judith Feinberg headshot.

Retire? No, Thanks! This Doc Instead Moved to West Virginia to Fight HIV, Hepatitis C, and the Opioid Crisis

In a poor and conservative state, Judith Feinberg, M.D., aims to expand harm reduction—and bring treatment to active drug users.

By Tim Murphy
Toby Pepperrell

Is Virologic Failure the Best Endpoint in Clinical Trials for Integrase Inhibitors?

Using data from the ADVANCE trial, this researcher suggests people with HIV with low-level viremia may still get to undetectable.

By Terri Wilder, M.S.W.
Brian Minalga

Transgender People Must Be Included in Every Aspect of HIV Research

Descovy’s approval for PrEP showcases real-life ramifications of leaving trans people out of research. But including trans people is about more than just saying trans people are welcome, says researcher Brian Minalga.

By Mathew Rodriguez